Your cart is empty.
Männedorf, Switzerland, April 14, 2014 - The Annual General Meeting of Tecan Group Ltd. (SIX Swiss Exchange: TECN) has today endorsed all motions proposed by the Board of Directors. Shareholders approved the Annual Report, the financial statements and the consolidated financial statements, and granted discharge to the Board of Directors and the Management Board. They also approved an unchanged dividend versus the previous year of CHF 1.50 per registered share. The payout will take place on April 23, 2014.
The Compensation Report, submitted for an advisory vote for the third year, was again accepted by shareholders.
All members of the Tecan Board of Directors, Heinrich Fischer, Dr. Oliver Fetzer, Dr. Karen Huebscher, Dr. Christa Kreuzburg, Gérard Vaillant, Erik Walldén and Rolf Classon, were re-elected for a further one-year term. Rolf Classon was confirmed by shareholders as Chairman of the Board. Dr. Oliver Fetzer and Dr. Christa Kreuzburg were elected by shareholders as members of the Compensation Committee.
KPMG AG, Zurich, was confirmed as the statutory auditors for fiscal year 2014.
Shareholders approved the motion proposed by the Board of Directors to appoint Proxy Voting Services GmbH, Zurich, as the independent proxy for the period up to the close of the Tecan Group 29th Annual General Meeting in 2015.
Board Chairman Rolf Classon commented: "I thank shareholders for their vote of confidence in the work of the Board and our mandated committees as well as in myself as Chairman."
Amendments to the Articles of Incorporation to increase financial flexibility and to meet new statutory requirements
Shareholders approved an amendment to the Articles of Incorporation to extend the authorized capital to April 14, 2016. This will give Tecan additional financial flexibility to exploit external growth opportunities.
Shareholders also approved a series of amendments to the Articles of Incorporation, enabling Tecan to already implement the provisions of the Swiss government Ordinance Against Excessive Compensation in Listed Companies (OeEC) to a large extend. The Ordinance was passed following approval by the Swiss population of an initiative in spring 2013, widely known as Minder Initiative.
Next key date
Tecan will publish the 2014 Interim Report on August 13, 2014.
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions
in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2013, Tecan generated sales of CHF 388 million (USD 419 million; EUR 316 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
Head of Corporate Communications & Investor Relations
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89